The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interferon-α-dependent Activation of Tyk2 Requires Phosphorylation of Positive Regulatory Tyrosines by Another Kinase
Open accessAbstract
Tyk2 and JAK1, members of the Janus kinase (JAK) family of protein tyrosine kinases, are required for interferon-alpha/beta binding and signaling. Both enzymes are associated with the interferon-alpha/beta receptor, and upon ligand binding, they undergo tyrosine phosphorylation and catalytic activation in an interdependent manner. To identify residues involved in Tyk2 regulation and to understand the basis of the interdependence of Tyk2 and JAK1, six mutated versions of Tyk2 bearing single or multiple point mutations in the tyrosine kinase domain were studied in a cell line lacking endogenous Tyk2. The Y1054F/Y1055F substitutions in the putative activation loop prevented ligand-dependent activation of Tyk2, without abolishing its catalytic potential. The K930R mutation in the ATP binding site generated a kinase-negative protein, which however, still became phosphorylated upon interferon-alpha treatment. The Y1054F/Y1055F substitutions in this kinase-negative Tyk2 abolished the induced phosphorylation. These results indicate that Tyk2 is activated by phosphorylation on Tyr-1054 and/or Tyr-1055 and that this phosphorylation requires another kinase, most likely JAK1. While the Tyk2 forms mutated on Tyr-1054 and Tyr-1055 or on Lys-930 allowed some inducible gene expression, the combination of the three point mutations totally abolished signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wilks, A. F., Harpur, A. G., Kurban, R. R., Ralph, S. J., Zürcher, G., & Ziemiecki, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.2057 · Cited by 528
Cited by
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N., et al. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1309 · Cited by 719
“Activation of JAK tyrosine kinase activity is positively regulated by transphosphorylation of a critical tyrosine within the activation loop of the kinase domain (Gauzzi et al., 1996; Feng et al., 1997; Liu et al., 1997; Zhou et al., 1997; Weiss and Schlessinger, 1998).”
BackgroundNegative Regulation of Cytokine Signaling Pathways
Yasukawa, H., Sasaki, A., & Yoshimura, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.143 · Cited by 598
Janus kinases: components of multiple signaling pathways
Rane, S. G., & Reddy, E. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203925 · Cited by 466
Jaks, STATs, Cytokine Signal Transduction, and Immunoregulation: Are We There Yet?
O'Shea, J. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80505-1 · Cited by 386
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Kovanen, P. E., & Leonard, W. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00203.x · Cited by 360
Feng, J., Witthuhn, B. A., Matsuda, T., Kohlhuber, F., Kerr, I. M., & Ihle, J. N. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2497 · Cited by 356
Complex roles of Stat1 in regulating gene expression
Ramana, C. V., Chatterjee-Kishore, M., Nguyen, H., & Stark, G. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203525 · Cited by 336
Majoros, A., Platanitis, E., Kernbauer-Hölzl, E., Rosebrock, F., Müller, M., & Decker, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00029 · Cited by 325
Differentiation therapy of human cancer: basic science and clinical applications
Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., & Fisher, P. B. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00132-2 · Cited by 292
Burke, J. R., Cheng, L., Gillooly, K. M., Strnad, J., Zupa-Fernandez, A., Catlett, I. M., Zhang, Y., Heimrich, E. M., McIntyre, K. W., Cunningham, M. D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1736 · Cited by 289
Pellegrini, S., & Dusanter‐Fourt, I. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00615.x · Cited by 281
Self-citationThe Receptor of the Type I Interferon Family
Uzé, G., Schreiber, G., Piehler, J., & Pellegrini, S. (2007) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-71329-6_5 · Cited by 260
Self-citationThe Type I Interferon Receptor: Structure, Function, and Evolution of a Family Business
Mogensen, K. E., Lewerenz, M., Reboul, J., Lutfalla, G., & Uzé, G. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099313019 · Cited by 252
Self-citationRegulation of Interferon-α Responsiveness by the Duration of Janus Kinase Activity
Lee, C.-K., Bluyssen, H. A. R., & Levy, D. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.21872 · Cited by 87
Gracias, S., Chazal, M., Decombe, A., Unterfinger, Y., Sogues, A., Pruvost, L., Robert, V., Lacour, S. A., Lemasson, M., Sourisseau, M., et al. (2023) · The EMBO Reports · doi:10.15252/embr.202357424 · Cited by 27
Self-citation
Metadata
- Authors
- Gauzzi, M. C., Velazquez, L., McKendry, R., Mogensen, K. E., Fellous, M., & Pellegrini, S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-08
- Volume
- 271
- Issue
- 34
- Pages
- 20494-20500
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1987274954
- Cited by
- 187
- References
- 1
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.